RCMI Coordinating Center (RCMI CC) Header Logo

Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.

Fortner RT, Schock H, Le Cornet C, H?sing A, Vitonis AF, Johnson TS, Fichorova RN, Fashemi T, Yamamoto HS, Tj?nneland A, Hansen L, Overvad K, Boutron-Ruault MC, Kvaskoff M, Severi G, Boeing H, Trichopoulou A, Papatesta EM, La Vecchia C, Palli D, Sieri S, Tumino R, Sacerdote C, Mattiello A, Onland-Moret NC, Peeters PH, Bueno-de-Mesquita HBA, Weiderpass E, Quir?s JR, Duell EJ, S?nchez MJ, Navarro C, Ardanaz E, Larra?aga N, Nodin B, Jirstr?m K, Idahl A, Lundin E, Khaw KT, Travis RC, Gunter M, Johansson M, Dossus L, Merritt MA, Riboli E, Terry KL, Cramer DW, Kaaks R. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort. Int J Cancer. 2018 04 01; 142(7):1355-1360.

View in: PubMed

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support